Atea Pharmaceuticals (AVIR)
(Delayed Data from NSDQ)
$3.47 USD
-0.17 (-4.67%)
Updated Aug 1, 2025 04:00 PM ET
After-Market: $3.46 -0.01 (-0.29%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth F Momentum D VGM
Fundamental Charts
About Dividend Yield (TTM)
Atea Pharmaceuticals, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
AVIR 3.47 -0.17(-4.67%)
Will AVIR be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for AVIR based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for AVIR
Is Atea Pharmaceuticals (AVIR) Stock Outpacing Its Medical Peers This Year?
Beam Therapeutics' Q3 Earnings & Revenues Fall Shy of Estimates
AVIR: What are Zacks experts saying now?
Zacks Private Portfolio Services
Apellis' Q3 Loss Wider Than Expected, Syfovre Drives Revenues Y/Y
VRTX Q3 Earnings & Sales Trump Estimates, '24 Sales View Raised
Transplant Logistic Service Business Likely to Aid TMDX's Q3 Earnings
Other News for AVIR
Atea Pharmaceuticals to Host Second Quarter 2025 Financial Results and Business Update ...
Atea Pharmaceuticals (AVIR) Launches Phase 3 Trial for Hepatitis C Treatment | AVIR Stock News
Atea Pharmaceuticals Announces Continued Advancement of Global Phase 3 HCV Program with Dosing ...
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial
Atea Pharmaceuticals announces first patient dosed in Phase 3 C-FORWARD trial